University Medicine Greifswald, Department of Neurology, Hansestadt Greifswald, Germany.
University Medicine Greifswald, Department of Neurology, Hansestadt Greifswald, Germany.
Epilepsy Res. 2014 May;108(4):623-33. doi: 10.1016/j.eplepsyres.2014.02.005. Epub 2014 Feb 18.
The antiepileptic drug valproic acid (VPA) has shown neuroprotective effects in different cell types including mesencephalic neural primary cultures. Furthermore, an influence on neural differentiation and neurite outgrowth has been described. Nevertheless, results in this regard are contradictory and data on long term expanded neural stem cells are missing. This is why we investigated possible neuroprotective effects of VPA on fetal mesencephalic neural stem cells (fmNSCs) in vitro, using the neurotoxic agent 1-methyl-4-phenyl-pyridin (MPP+). We also examined potential VPA effects on cell expansion and differentiation and the underlying signaling pathways. In our study, we could exclude any relevant toxic effects of 100 μg/ml and 200 μg/ml VPA on fmNSCs during expansion and differentiation for up to 96 h. MPP+ treatment in concentrations of 30 and 60 μM MPP+ significantly decreased the survival rate of fmNSCs during expansion and differentiation. In all used concentrations, VPA did neither reverse these MPP+ effects when applied simultaneously with MPP+ nor after pre-treatment with VPA for 24 h. In contrast, MPP+ effects were emphasized by VPA pretreatment for 24h when applied during cell expansion. Concerning the self-renewing capacity of fmNSCs, measured by BrdU and Ki67 staining, we did not find any significant influence of VPA. Additionally there was no significant influence of therapeutic VPA dosages on astroglial (GFAP), oligodendroglial (GalC) and neuronal (MAP2) differentiation, measured by immunostaining after 10 days of differentiation. Summing up, we did not find any neuroprotective effects of VPA on fmNSCs in vitro, neither during expansion nor during cell differentiation. Also the self-renewing and differentiation potential of the used fmNSCs was not altered. These findings have implications for the large community of patients having to take VPA on a chronic base, especially in the light of knowledge that a regular cell replacement out of hippocampal adult stem cells is mandatory for the maintenance of normal cognition through adulthood.
抗癫痫药物丙戊酸(VPA)已在包括中脑神经原代培养物在内的不同细胞类型中显示出神经保护作用。此外,已经描述了对神经分化和突起生长的影响。尽管如此,这方面的结果却存在矛盾,并且缺乏关于长期扩增神经干细胞的数据。这就是为什么我们在体外研究了 VPA 对胎鼠中脑神经干细胞(fmNSC)的可能神经保护作用,使用神经毒性剂 1-甲基-4-苯基-1,2,3,6-四氢吡啶(MPP+)。我们还检查了 VPA 对细胞扩增和分化以及潜在信号通路的潜在影响。在我们的研究中,我们可以排除 100μg/ml 和 200μg/ml VPA 在长达 96 小时的扩增和分化过程中对 fmNSC 的任何相关毒性作用。30μM 和 60μM MPP+浓度的 MPP+处理显着降低了扩增和分化过程中 fmNSC 的存活率。在所有使用的浓度下,当与 MPP+同时应用时,VPA 既没有逆转这些 MPP+的作用,也没有在 VPA 预处理 24 小时后进行。相反,当在细胞扩增过程中应用时,VPA 预处理 24 小时会增强 MPP+的作用。关于 fmNSC 的自我更新能力,通过 BrdU 和 Ki67 染色测量,我们没有发现 VPA 的任何显着影响。此外,在分化 10 天后通过免疫染色测量,治疗性 VPA 剂量对星形胶质细胞(GFAP)、少突胶质细胞(GalC)和神经元(MAP2)分化也没有显着影响。总之,我们没有发现 VPA 对体外 fmNSC 的任何神经保护作用,无论是在扩增过程中还是在细胞分化过程中。使用的 fmNSC 的自我更新和分化潜能也没有改变。这些发现对大量需要长期服用 VPA 的患者群体具有重要意义,特别是考虑到这样一个知识,即从海马体成年干细胞中进行定期细胞替换对于维持成年期的正常认知是必需的。